EGEN is actively engaged in development and discovery research. Our most advanced product is currently being clinically evaluated as a cancer immunotherapy. A number of other projects are directed towards various types of cancer and other human diseases. Research at EGEN is mainly directed towards the delivery of DNA and RNA (siRNA and shRNA) utilizing proprietary synthetic carrier systems. The chart below shows the progress of research at EGEN.